Research Article|Articles in Press

External multicentre validation of pseudomyxoma peritonei PSOGI-Ki67 classification

Published:March 14, 2023DOI:



      Pseudomyxoma peritonei (PMP) is a rare malignant disease. Adding of the Ki67 proliferation index to the PSOGI PMP classification provided two different subcategories of the extensive HG-PMP group (HG-PMP ≤15% and HG-PMP >15%) with different survival in a previous unicentric study. This study aims to carry out an external and multicentre validation of this new proposed classification.


      It was a prospective analysis of samples from a historical and international cohort of patients. A representative area with higher cellular density was used to determine the Ki67%. The Ki67 proliferation index (%) was determined in all the HG-PMP patients. A Cox proportional hazard models and multivariable COX models were used. The Kaplan–Meier method and the two-tailed log-rank test were used to analyse the effect of different PSOGI-Ki67 categories on OS and DFS. Its predictive accuracy was analysed using Harrel's C-index and the ROC curve. The calibration was performed using the calibration plots matching.


      After exclusions, 349 patients were available for analysis. The 5-years OS were 86% for LG-PMP, 59% for HG-PMP≤15, 38% for HG-PMP>15 and 42% for SRC-PMP (p = 0.0001). The 5-years DFS were 49% for LG-PMP, 35% for HG-PMP≤15, 16% for HG-PMP>15 and 18% SRC-PMP (p = 0.0001). The discrimination capability of PSOGI-Ki67 was validated.
      Conclusion: the PSOGI-Ki67 classification discriminates and predicts the OS and DFS in patients with PMP dividing the HG-PMP category into two well-defined sub-categories. The Ki67 proliferation index should be incorporated routinely in the pathology report for these patients.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Surgical Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Mittal R.C.A.
        • Moran B.
        Pseudomyxoma peritonei: natural history and treatment.
        Int J Hyperther. 2017; 33: 511-519
        • Govaerts K.
        • Lurvink R.J.
        • De Hingh I.H.J.T.
        • et al.
        PSOGI. Appendiceal tumours and pseudomyxoma peritonei: literature review with PSOGI/EURACAN clinical practice guidelines for diagnosis and treatment.
        Eur J Surg Oncol. 2020; 28 (S0748-7983(20)30114-1)
        • Carr N.J.
        • Mohamed F.
        • et al.
        A consensus for classification and pathologic reporting of pseudomyxoma peritonei and associated appendiceal Neoplasia: the results of the peritoneal Surface Oncology group international (PSOGI) modified delphi process.
        Am J Surg Pathol. 2016; 40: 14-26
        • Rufián-Andujar B.
        • Valenzuela-Molina F.
        • Rufián-Peña S.
        • et al.
        From the ronnett to the PSOGI classification system for pseudomyxoma peritonei: a validation study.
        Ann Surg Oncol. 2021 May; 28: 2819-2827
        • Baratti D.
        • Kusamura S.
        • Milione M.
        • et al.
        Validation of the recent PSOGI pathological classification of pseudomyxoma peritonei in a Single-Center Series of 265 patients treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
        Ann Surg Oncol. 2018 Feb; 25: 404-413
        • Martín-Román L.
        • Lozano P.
        • Gómez Y.
        • et al.
        Which classification system defines best prognosis of mucinous neoplasms of the appendix with peritoneal dissemination: TNM vs PSOGI?.
        J Clin Pathol. 2021 Nov 1; (jclinpath-2021-207883)
        • Lund-Andersen C.T.A.
        • Fleten K.G.
        • et al.
        Omics analyses in peritoneal metastasis—utility in the management of peritoneal metastases from colorectal cancer and pseudomyxoma peritonei: a narrative review.
        J Gastrointest Oncol. 2021; 12: S191-S203
        • Shetty S.T.P.
        • Bala Ramanan B.
        Kras mutations and p53 overexpression in pseudomyxoma peritonei: association with phenotype and prognosis.
        J Surg Res. 2013; 180: 97-103
        • Pietrantonio F.P.F.
        • Mennitto A.
        • et al.
        Toward the molecular dissection of peritoneal pseudomyxoma.
        Ann Oncol. 2016; 27: 2097-2103
      1. a
        • Yan F.L.Y.
        • Zhou Q.
        • et al.
        Pathological prognostic factors of pseudomyxoma peritonei: comprehensive clinicopathological analysis of 155 cases.
        Hum Pathol. 2020; 97: 9-18
      2. b
        • Menona S.S.G.C.
        • Sakthivelc K.M.
        • et al.
        Ki-67 protein as a tumour proliferation marker.
        Clin Chim Acta. 2019; 491: 39-45
        • Deraco M.
        • Cabras A.
        • Baratti D.
        • et al.
        Immunohistochemical evaluation of minichromosome maintenance protein 7 (MCM7), Topoisomerase IIα, and Ki-67 in diffuse malignant peritoneal mesothelioma patients using tissue microarray.
        Ann Surg Oncol. 2015 Dec; 22: 4344-4351
        • Arjona-Sánchez Á.
        • Martínez-López A.
        • Valenzuela-Molina F.
        • et al.
        A proposal for modification of the PSOGI classification according to the Ki-67 proliferation index in pseudomyxoma peritonei.
        Ann Surg Oncol. 2022; : 126-136
        • Moaven O.
        • Su J.
        • Jin G.
        • et al.
        Clinical Implications of Genetic Signatures in appendiceal cancer patients with Incomplete cytoreduction/HIPEC.
        Ann Surg Oncol. 2020; 27: 5016-5023
        • Ramspek Chava L.
        • Jager Kitty J.
        • Dekker Friedo W.
        • et al.
        External validation of prognostic models: what, why, how, when and where?.
        Clin Kidney J. 2021; 14: 49-58
        • Bosman FC F.
        • Hruban R.
        WHO classification of tumours.
        Digestive System Tumours, 2019
        • Menona S.S.
        • Guruvayoorappan C.
        • Sakthivelc K.M.
        • et al.
        Ki-67 protein as a tumour proliferation marker.
        Clin Chim Acta. 2019; 491: 39-45
        • Foster Jason M.
        • Zhang Chunmeng
        • Rehman Shahyan
        • et al.
        The contemporary management of peritoneal metastasis:A journey from the cold past of treatment futility to a warm present and a bright future CA Cancer.
        J Clin. 2022; (0): 1-23